HUTCHMED Highlights Surufatinib and Toripalimab Combination

Hong Kong, Shanghai & Florham Park, NJ — Friday, December 10, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new analyses and updates on the ongoing studies of surufatinib combined with toripalimab, in multiple disease settings, presented at the Europ...

Related Keywords

Jilin , China , Ying Cheng , Hubei , United States , Peking , Beijing , Hong Kong , Ming Lu , Hunan , Zhou Yi , Atholl Tweedie Freddy Crossley , Ben Atwell Alex Shaw , Mark Lee , Junshi Biosciences , Annie Cheng , Stock Exchange Of Hong Kong , Linkedin , University Cancer Hospital Institute , Drug Administration , Surufatinib Development , Nasdaq , Exchange Commission , China Limited , Oncology Congress , European Medicines Agency , National Medical Products Administration Of China , European Society For Medical Oncology , Florham Park , European Society , Medical Oncology , Immuno Oncology Congress , Jilin Cancer , Peking University Cancer Hospital , Neuroendocrine Tumors , National Medical Products Administration , Pancreatic Neuroendocrine Tumors , Lancet Oncology , New Drug Application , Marketing Authorisation Application , Fast Track Designations , Orphan Drug Designation , Expanded Access Protocol , Southeast Asia , Biologics License Application , Securities Litigation Reform Act , Stock Exchange , Hong Kong Limited , Senior Vice , Brad Miles , Ben Atwell , Alex Shaw , Freddy Crossley , United Kingdom ,